|
Switzerland-De-De Azienda Directories
|
Azienda News:
- Lung Cancer - Medscape
Lung Cancer : Review in-depth clinical information, latest medical news, and guidelines on lung cancer, specifically small-cell lung cancer and non-small-cell lung cancer Read the latest
- Small Cell Lung Cancer in 2024: Treatment Advances - Medscape
In 2024 for small cell [lung cancer], there’s a clear benefit of durvalumab in limited-stage disease Tarlatamab is another drug that can provide benefit to our patients, but how to choose
- Two Lung Cancer Drugs Recommended by EMA - Medscape
Is Consolidation Osimertinib Superior to Durvalumab in EGFR-Mutated Non–Small Cell Lung Cancer? Small Cell Lung Cancer in 2024: Treatment Advances 3090D553-9492-4563-8681-AD288FA52ACE
- Advanced Non-Small Cell Lung Cancer Updates From ASCO 2024 - Medscape
Practice-changing studies in advanced non-small cell lung cancer presented at ASCO 2024 are reviewed by Dr Ticiana Leal, including the phase 3 LAURA and PALOMA-3 studies and a 5-year update of CROWN
- Why a New Inhalable Lung Cancer Treatment Is So Promising - Medscape
Cheng, who has been developing exosome and stem cell therapies for more than 15 years, and his lab team focused on lung cancer because the disease, often detected in later stages, "has a huge
- Changes in the Treatment Landscape of Early-Stage Non-Small Cell Lung . . .
Dr Narjust Florez explores the transformative shifts in the treatment landscape for early-stage non–small cell lung cancer over the years, particularly emphasizing the significant changes
- A ‘Fool’s Errand’? Picking a Winner for Treating Early NSCLC
Is Consolidation Osimertinib Superior to Durvalumab in EGFR-Mutated Non–Small Cell Lung Cancer? Small Cell Lung Cancer in 2024: Treatment Advances 3090D553-9492-4563-8681-AD288FA52ACE
- Potential Drivers of LCINS - Medscape
During a plenary session at the 2024 World Congress on Lung Cancer, experts addressed the known and suspected causes of LCINS, including fallout from climate change, vaping, cannabis use, and
- Zenocutuzumab Effective Against NRG1 Fusion Cancers - Medscape
IASLC Issues Consensus on Neoadjuvant, Adjuvant Treatments in Non–Small Cell Lung Cancer Is Consolidation Osimertinib Superior to Durvalumab in EGFR-Mutated Non–Small Cell Lung Cancer
- Evaluation and Management of Small Pulmonary Nodules - Page 3 - Medscape
Lung nodules in the right lung and in the upper lobes have a higher probability for malignancy [ 17 , 45 ] Some studies indicate that 70% of all lung cancers are located in the upper lobes
|
|